This is a HIA partner technology
A device that increases blood flow to the left atrial appendage via a “sprayer”. This sprayer is a tube that begins in the left appendage and directs a portion of the blood flow directly into the left atrial appendage.
Wet macular degeneration is the advanced stage of age-related macular degeneration (AMD) and affects approximately 10-15% of patients with AMD, yet accounts for more than 80% of all vision loss associated with the disease. Wet AMD is caused by abnormal blood vessel growth in the retina, known as choroidal neovascularization.
Mitotic kinesins are motor proteins required to facilitate proper cell division (mitosis). Recent studies by Dr. Rosenfeld and his team have shown that one of these kinesins, Eg5, is up-regulated in tumor cells from human glioblastomas.
AppointmentPass™ is a technology that creates efficiency in the appointment check-in process. It is comprised of proprietary software coupled with off the shelf tablets and kiosk hardware.
Aptamers are oligonucleotide or peptide molecules that bind to a specific target molecule. Dr. Rich and his team have developed aptamers consisting of a single stranded nucleic acids having 100 nucleotides or less that specifically binds to tumor initiating cancer cells, identified by screening a large pool of randomly generated aptamers to obtain a discrete set of them that specifically bind to tumor initiating cancer cells, such as those found in brain cancer or glioblastoma.
The complement system is emerging as a new target for treating many diseases. For example, Eculizumab, a humanized monoclonal antibody against complement component 5 (C5), has been approved for paroxysmal nocturnal hemoglobinuria (PNH) in which patient erythrocytes are lysed by complement.
The AZ Airway provides the ability to ventilate supraglottically and/or infraglottically in a single device.
The invention is a system of multiple devices and a set of methods that can be used to enhance the short term structural properties of cancellous bone.
The BrainFORCETM mTBI Screening tool is a rapid assessment test (<10 min) designed to be used in the field (athletic or battle) as the first in battery of tests to diagnose mTBI.
Tumors adapt their phenotypes during growth and in response to therapies through
dynamic changes in cellular processes. The connexin family proteins enable such dynamic changes during development and their dysregulation leads to disease states. The cellular networks formed by connexins have been reported to exhibit tumor-suppressive functions, including in triple-negative breast cancer (TNBC).